JP2020502104A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502104A5
JP2020502104A5 JP2019531589A JP2019531589A JP2020502104A5 JP 2020502104 A5 JP2020502104 A5 JP 2020502104A5 JP 2019531589 A JP2019531589 A JP 2019531589A JP 2019531589 A JP2019531589 A JP 2019531589A JP 2020502104 A5 JP2020502104 A5 JP 2020502104A5
Authority
JP
Japan
Prior art keywords
sequence
chain
protein
selenocysteine
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019531589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502104A (ja
JP7186400B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/049354 external-priority patent/WO2018045018A1/en
Publication of JP2020502104A publication Critical patent/JP2020502104A/ja
Publication of JP2020502104A5 publication Critical patent/JP2020502104A5/ja
Priority to JP2022184852A priority Critical patent/JP7378106B2/ja
Application granted granted Critical
Publication of JP7186400B2 publication Critical patent/JP7186400B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019531589A 2016-08-30 2017-08-30 ゲノム的に再コードした生物におけるセレノ-生物製剤の製造 Active JP7186400B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022184852A JP7378106B2 (ja) 2016-08-30 2022-11-18 ゲノム的に再コードした生物におけるセレノ-生物製剤の製造

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662381316P 2016-08-30 2016-08-30
US62/381,316 2016-08-30
US201762537986P 2017-07-28 2017-07-28
US62/537,986 2017-07-28
PCT/US2017/049354 WO2018045018A1 (en) 2016-08-30 2017-08-30 Production of seleno-biologics in genomically recoded organisms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022184852A Division JP7378106B2 (ja) 2016-08-30 2022-11-18 ゲノム的に再コードした生物におけるセレノ-生物製剤の製造

Publications (3)

Publication Number Publication Date
JP2020502104A JP2020502104A (ja) 2020-01-23
JP2020502104A5 true JP2020502104A5 (enExample) 2020-10-08
JP7186400B2 JP7186400B2 (ja) 2022-12-09

Family

ID=61301655

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531589A Active JP7186400B2 (ja) 2016-08-30 2017-08-30 ゲノム的に再コードした生物におけるセレノ-生物製剤の製造
JP2022184852A Active JP7378106B2 (ja) 2016-08-30 2022-11-18 ゲノム的に再コードした生物におけるセレノ-生物製剤の製造

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022184852A Active JP7378106B2 (ja) 2016-08-30 2022-11-18 ゲノム的に再コードした生物におけるセレノ-生物製剤の製造

Country Status (5)

Country Link
US (1) US11492650B2 (enExample)
EP (1) EP3506945A4 (enExample)
JP (2) JP7186400B2 (enExample)
CN (1) CN109803679A (enExample)
WO (1) WO2018045018A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. ANTIBODIES AND CONJUGATES THEREOF
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US11155804B2 (en) 2016-07-11 2021-10-26 Board Of Regents, The University Of Texas System Recombinant polypeptides comprising selenocysteine and method for producing the same
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
CN112673100B (zh) * 2018-07-09 2025-04-29 格罗生物科学公司 包括非标准氨基酸的组合物及其用途
EP3956355B1 (en) * 2019-04-19 2025-11-26 The Trustees of Indiana University Stabilization of prandial or basal insulin analogues by an internal diselenide bridge
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
IL293450A (en) 2019-12-03 2022-07-01 Evotec Int Gmbh Interferon-associated antigen binding proteins and uses thereof
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
TW202228775A (zh) 2020-10-14 2022-08-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物及方法
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
WO2023051680A1 (zh) * 2021-09-30 2023-04-06 正大天晴药业集团股份有限公司 针对免疫检查点的双特异性抗体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849417B1 (en) 1998-04-06 2005-02-01 The United States Of America As Represented By The Department Of Health And Human Services Mammalian selenoprotein differentially expressed in tumor cells
WO2001012657A2 (en) 1999-08-16 2001-02-22 Karolinska Innovations Ab Methods and means for selenoprotein expression
WO2007075438A2 (en) 2005-12-15 2007-07-05 Codon Devices, Inc. Polypeptides comprising unnatural amino acids, methods for their production and uses therefor
US20090155255A1 (en) 2007-09-27 2009-06-18 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
AU2012216723B2 (en) * 2007-11-20 2014-08-28 Ambrx, Inc. Modified insulin polypeptides and their uses
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
JP5572972B2 (ja) * 2009-03-16 2014-08-20 Jnc株式会社 インスリン分泌促進剤などの薬物のスクリーニング方法
AU2011301147A1 (en) * 2010-09-08 2013-04-18 Howard Florey Institute Of Experimental Physiology And Medicine Modified relaxin polypeptides
BR112013019150A2 (pt) 2011-01-28 2019-09-24 Nat Res Council Canada engenharia do âmbito da imunoglobulina
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
US9464288B2 (en) * 2011-07-11 2016-10-11 Yale University Compositions and methods for making selenocysteine containing polypeptides
US10240158B2 (en) 2011-07-11 2019-03-26 Yale University Compositions and methods for making selenocysteine containing polypeptides
US10876142B2 (en) 2011-07-11 2020-12-29 Yale University Compositions and methods for making selenocysteine containing polypeptides
US10351626B2 (en) 2013-03-14 2019-07-16 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
US20150050682A1 (en) 2013-08-15 2015-02-19 University Of Vermont And State Agricultural College Direct assay of thioredoxin reductase activity
US10519247B2 (en) 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
US10118950B2 (en) 2014-08-30 2018-11-06 Northwestern University Platforms for cell-free protein synthesis comprising extracts from genomically recoded E. coli strains having genetic knock-out mutations in release factor 1 (RF-1) and endA
WO2016172269A2 (en) 2015-04-20 2016-10-27 University Of Utah Research Foundation Insulin analogs having shortened b chain peptides and associated methods
CN105111304B (zh) * 2015-09-30 2018-12-14 山东阿华生物药业有限公司 重组人胰岛素前体的纯化和酶切转换方法
US10557160B2 (en) 2015-12-15 2020-02-11 Board Of Regents, The University Of Texas System Transgenic bacteria with expanded amino acid usage and nucleic acid molecules for use in the same
US11155804B2 (en) 2016-07-11 2021-10-26 Board Of Regents, The University Of Texas System Recombinant polypeptides comprising selenocysteine and method for producing the same
MA45727A (fr) * 2016-07-22 2019-05-29 Walter & Eliza Hall Inst Medical Res Analogues de l'insuline
CA3030930A1 (en) 2016-07-22 2018-01-25 University Of Utah Research Foundation Insulin analogs
EP3956355B1 (en) 2019-04-19 2025-11-26 The Trustees of Indiana University Stabilization of prandial or basal insulin analogues by an internal diselenide bridge

Similar Documents

Publication Publication Date Title
JP2020502104A5 (enExample)
CO2020001113A2 (es) Muteínas de interleucina 21 y métodos de tratamiento
PH12020551317A1 (en) Anti-cd73 antibodies and methods of use thereof
JP2020503891A5 (enExample)
JP2014000092A5 (enExample)
JP2016526909A5 (enExample)
AR095432A1 (es) Proteínas de unión a antígeno
AR075504A1 (es) Moleculas de anticuerpos que tienen especificidad para el ox40 humano
JP2020501550A5 (enExample)
PE20232039A1 (es) Mutantes de proteina f de rsv
JP2015525217A5 (enExample)
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JP2015212284A5 (enExample)
JP2017538401A5 (enExample)
JP2018033454A5 (enExample)
AR075047A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit.
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
PE20161221A1 (es) Anticuerpos de il-21
FI3452507T3 (fi) Tau-immuunihoito
CN113366016A (zh) 抗人白细胞介素5(il-5)单克隆抗体及其应用
JP2019505567A5 (enExample)
PH12022550460A1 (en) Anti-cd96 antibodies and methods of use thereof
JP2013523718A5 (enExample)
JP2015521206A5 (enExample)
AR099068A1 (es) Anticuerpo anti-netrina-1